New Inversion Data Reveals Six Anomalies at Aurania's Awacha Target
Newsfile· 2025-06-27 11:00
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) ("Aurania" or the "Company") reports that reprocessing Mobile MagnetoTellurics (MobileMT) data from the Company's Awacha porphyry copper target in Ecuador using the latest 2D inversion technology has revealed six highly conductive anomalies.In 2021, Aurania contracted Expert Geophysics Surveys Inc. to conduct a MobileMT airborne survey over the Awacha porphyry copper target area. At that time, ...
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
Globenewswire· 2025-06-27 11:00
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines’ daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer. “Almost all MTAP-de ...
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Globenewswire· 2025-06-27 10:50
Core Insights - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][3] Company Overview - Pharvaris aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies for the prevention and treatment of bradykinin-mediated angioedema attacks [3] - The company is currently evaluating the efficacy and safety of its lead candidate, deucrictibant, in pivotal Phase 3 studies for both prophylaxis and on-demand treatment of HAE attacks [3] Upcoming Presentations - Pharvaris announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit, scheduled for July 10-13, 2025, in Baltimore, Maryland [1] - Multiple poster presentations will be held on July 11, 2025, featuring various studies related to deucrictibant, including long-term safety and efficacy, disease control, and health-related quality of life improvements in HAE patients [2][4]
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
Globenewswire· 2025-06-27 10:50
Core Insights - Eton Pharmaceuticals has been added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market closes on June 27, 2025, marking a significant milestone for the company [1][2]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products and five additional candidates in late-stage development [4]. Market Impact - The inclusion in the Russell indexes is expected to enhance Eton's visibility among investors and reflects the shareholder value generated over the past year [2][3]. Product Portfolio - Eton's commercial rare disease products include KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, with late-stage candidates including ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [4].
1 Thing Every Lucid Group Investor Needs to Watch Right Now
The Motley Fool· 2025-06-27 10:47
It's an exciting time for Lucid Group (LCID 2.80%). Sales are expected to grow by 72% this year and 97% next year thanks to the recent introduction of its Gravity SUV platform. Plus, several new models may be on the way as early as 2026. But there's one critical risk point that every investor should be monitoring right now. Could this 1 change kill Lucid Group stock?Few companies completely control their own destiny. But some are more exposed to outside events than others. Right now, Lucid is particularly v ...
2 Tech Stocks I'd Buy and Never Sell
The Motley Fool· 2025-06-27 10:45
Everyone thinks they know what Meta Platforms (META 2.54%) and Tesla (TSLA -0.31%) are -- a social media company and an electric vehicle (EV) maker. But what if I told you that's like calling Amazon a bookstore? The real story is far more intriguing, and it's unfolding right now.Here's why these two tech giants deserve a permanent spot in your portfolio. The stealth transformation into an AI powerhouseMark Zuckerberg is spending money like a man possessed. The Facebook founder just dropped $14.3 billion to ...
Meta in talks to acquire voice cloning startup Play AI
TechCrunch· 2025-06-27 10:38
Core Insights - Meta is looking to enhance its AI capabilities by potentially acquiring Play AI, a voice cloning startup, to integrate voice technology into its offerings [1][3] - Play AI has developed technology that allows users to clone various voices for applications like customer service, and has raised a total of $23.5 million from notable investors [2] - The acquisition would enable Meta to expand its creative suite by adding audio features, complementing its existing chatbot functionalities [3]
Got $5,000? These 3 Artificial Intelligence Stocks Are Absurdly Cheap Right Now.
The Motley Fool· 2025-06-27 10:35
If you have $5,000 to invest in the market, one way to make the most of that money is to invest in stocks that have a lot of room for long-term growth, such as those involved in artificial intelligence (AI). Another way you can expand the potential of your investment is to focus on stocks that are also trading at cheap valuations, since they may be undervalued and possess even greater potential to generate significant returns.Three stocks that check off both boxes are Taiwan Semiconductor Manufacturing (TSM ...
Cango Inc. Announces Closing of Share-Settled Crypto Mining Assets Acquisitions
Prnewswire· 2025-06-27 10:30
Core Viewpoint - Cango Inc. has successfully completed the acquisition of on-rack crypto mining machines with a total hashrate of 18 Exahash per second, issuing 146,670,925 Class A ordinary shares to the sellers as part of the Share-Settled Transactions [1][2]. Group 1: Acquisition Details - The On-Rack Sales and Purchase Agreement for the Share-Settled Transactions was signed on November 6, 2024, with several amendments made leading up to the closing on June 27, 2025 [2]. - All closing conditions for the Share-Settled Transactions were satisfied or waived, including the NYSE's authorization for the supplemental listing application regarding the Class A ordinary shares [2]. Group 2: Ownership Structure - Following the completion of the Share-Settled Transactions, Golden TechGen Limited, the largest seller, now owns approximately 19.85% of Cango's total outstanding shares, while all sellers collectively own about 41.38% of the total outstanding shares before any Bonus Shares or Adjustment Shares are issued [3]. Group 3: Operational Aspects - The acquired mining machines are currently operational and located in data centers across several countries, predominantly in the U.S. Cango will continue to host these machines and has engaged a service provider for operational and maintenance services [4]. - The completion of these transactions is expected to bolster Cango's expansion and growth within the crypto asset sector [4]. Group 4: Company Overview - Cango Inc. is primarily focused on Bitcoin mining, with operations strategically located in North America, the Middle East, South America, and East Africa. The company entered the crypto asset space in November 2024, motivated by advancements in blockchain technology and the increasing adoption of digital assets [5].
Hyperscale Data Subsidiary Bitnile.com Now Accepting All Verified Solana-Based $SOL Tokens, Including Meme Coins
Globenewswire· 2025-06-27 10:30
Core Viewpoint - Hyperscale Data, Inc. has announced that its subsidiary Bitnile.com will accept all verified Solana-based tokens as payment on its social-casino platform, enhancing user engagement and expanding its service offerings [1][2][3]. Group 1: Company Developments - Bitnile.com has begun accepting verified Solana-based tokens, including trending coins like $BONK and $TRUMP, which allows users to engage with their communities while using the platform [1][3]. - The company aims to create a highly inclusive and flexible social-casino platform, targeting a broader user base by providing diverse onboarding options [2][3]. - Hyperscale Data operates a data center through its subsidiary Sentinum, which mines digital assets and offers colocation and hosting services for AI ecosystems and other industries [4]. Group 2: Strategic Initiatives - Hyperscale Data plans to divest its subsidiary ACG by December 31, 2025, focusing solely on data center operations to support high-performance computing (HPC) services [5]. - The divestiture will involve an exchange of Series F Preferred Stock for shares of Class A and Class B Common Stock of ACG, allowing stockholders to become ACG shareholders [6]. Group 3: Industry Context - The Solana ecosystem is rapidly expanding with new projects in decentralized finance, non-fungible tokens, gaming, and more, positioning Bitnile to capture a wider audience [2]. - The integration of Solana-based tokens enables fast, low-fee transactions and real-time compatibility with trending coins, enhancing the user experience on Bitnile.com [8].